EUVIMEDEUVIMED entdecken
Crossref

Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer

Yu Guo, Jiaxing Pan, Junjue Wang, Huijuan Zhang, Wenfang Yang, Fangmin Chen, Bowen Yin, Xiran Cai, Wei Tao iD, Twan Lammers iD, Yi Lai, Haijun Yu iD und 2 weitere

Journal of the American Chemical Society · 2025

DOI: 10.1021/jacs.5c00124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Yu Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin 300130, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunotherapy, Prodrugs, Antineoplastic Agents. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sonodynamic therapy (SDT) represents a promising approach for localized immunotherapy of solid tumors, yet its clinical translation is limited by therapy stress-induced adaptive immune resistance. Here, we demonstrate that SDT initially elicits antitumor immune response while consequently induces immunometabolic dysregulation via the interferon-gamma (IFN-γ)/indoleamine-2,3-dioxygenase-1 (IDO-1) axis to promote regulatory T cell (Treg) expansion. To counteract this negative regulation mechanism, we develop a sono-activatable prodrug (MB-MT) by conjugating the sonosensitizer methylene blue (MB) with the IDO-1 inhibitor 1-methyltryptophan (MT) via an ultrasound-labile urea bond. MB-MT is further incorporated into a thermosensitive hydrogel to yield an ultrasound-responsive immunogel that enables spatiotemporally confined SDT while locally suppressing IDO-1-mediated immune suppression. The combination of the immunogel with SDT treatment markedly normalizes the immunosuppressive tumor microenvironment to inhibit primary and metastatic tumor growth, and prevent postoperative recurrence in multiple synergistic mouse models of triple negative breast cancer (TNBC). This work presents a practical strategy for localized immunotherapy of TNBC by spatiotemporally confined normalization of immunometabolism disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunotherapyProdrugsAntineoplastic AgentsHydrogelsUltrasonic TherapyAnimalsFemaleMiceTryptophanHumansIndoleamine-Pyrrole 2,3,-DioxygenaseCell Line, TumorMethylene Blue

Substanzen

TryptophanIndoleamine-Pyrrole 2,3,-DioxygenaseProdrugs1-methyltryptophanMethylene BlueAntineoplastic AgentsHydrogels

Autor:innen und Institutionen

  • Institute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin 300130, China.
  • State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China.
  • Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • School of Information Science and Technology and the Shanghai Engineering Research Center of Intelligent Vision and Imaging, Shanghai Tech University, Shanghai 201210, China.
  • Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.

ORCID-Profile: Wei Tao, Twan Lammers, Haijun Yu, Xiuli Hu, Zhiai Xu

Förderung

  • Natural Science Foundation of Hebei Province
  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Open Funds of State Key Laboratory of Drug Research

Zitieren

APA

Guo, Y., Pan, J., Wang, J., Zhang, H., Yang, W., Chen, F., Yin, B., Cai, X., Tao, W., Lammers, T., Lai, Y., Yu, H., Hu, X., & Xu, Z. (2025). Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c00124

Vancouver

Guo Y, Pan J, Wang J, Zhang H, Yang W, Chen F, et al. Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer. Journal of the American Chemical Society. 2025. doi:10.1021/jacs.5c00124

BibTeX
@article{Guo2025,
  author = {Guo, Yu and Pan, Jiaxing and Wang, Junjue and Zhang, Huijuan and Yang, Wenfang and Chen, Fangmin and Yin, Bowen and Cai, Xiran and Tao, Wei and Lammers, Twan and Lai, Yi and Yu, Haijun and Hu, Xiuli and Xu, Zhiai},
  title = {Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer},
  journal = {Journal of the American Chemical Society},
  year = {2025},
  doi = {10.1021/jacs.5c00124}
}
Kostenlos starten →